Boston, Mass. — Drug-releasing devices that reside in the stomach for extended periods of time make it easier for patients to receive their full course of treatment. Instead of having to take a pill every day for a long period of time, a drug-delivery vehicle that slowly releases individual doses of medication could be administered once but provide medication for weeks or months.
Swallowable drug delivery systems are typically made of tough plastics such as thermoplastics or thermosets, but these materials present safety concerns in that they can cause physical obstructions in the gastrointestinal (GI) tract and are difficult to remove in the case of an allergic reaction. Instead, hydrogels, which are softer and potentially more biocompatible, are an appealing alternative for gastric resident systems. In a new study published in Nature Communications, researchers from Brigham and Women's Hospital, Massachusetts Institute of Technology and the Koch Institute for Integrative Cancer Research created a novel hydrogel material. The hydrogel is tough and triggerable, meaning it can withstand the forces of the GI environment and can be triggered to dissolve using an external stimulus.
"A lot of our work is centered on the concept of making it easier for patients to take their medications. A triggerable, tough hydrogel allows us to create systems that can easily deliver drugs over long periods of time while simultaneously addressing several of the chief safety concerns of these types of devices," said corresponding author Carlo "Gio" Traverso, MB, PhD, of the Division of Gastroenterology at BWH.
Hydrogels are appealing for a number of reasons. They are mainly composed of water so they can shrink in their dry state to become small enough to swallow, and then can expand and swell in the stomach to avoid passing into the small intestine. They can also be loaded with medicine and release it in a controlled manner.
However, the challenge with classic hydrogels is that they are relatively weak. The gastric cavity experiences significant forces associated with contractions of the stomach, so the new hydrogels need to be tough enough to withstand the strain.
Hydrogels are composed of a "net" of polymer chains. To toughen them up, the researchers created a double network hydrogel composed of two interwoven polymer nets. The next step was to make these hydrogels dissolvable in case the drug-delivery system needed to be removed quickly. They designed the hydrogel to be triggered to dissolve if the biocompatible agents EDTA (ethylenediaminetetraacetic acid) and GSH (glutathione) are consumed. The combination of EDTA and GSH can quickly break down the cross-links holding the two polymer nets together.
The researchers tested the tough, triggerable hydrogels in a large animal model which demonstrated the potential of this material.
"This material represents one of the first examples of a triggerable, tough hydrogel and could thus be used in many different applications such as supporting stem cell growth in the lab or in bariatric medicine," said Traverso. The next step in their research will be additional pre-clinical studies to further test the safety and stress resistance of the hydrogels before they can be used in people.
"We are really excited about the development of this new family of hydrogels and their potential to permit numerous new medical applications," says Robert Langer, Professor at the Massachusetts Institute of Technology Robert Langer
This research was funded in part by the Bill and Melinda Gates Foundation, National Institutes of Health as well as the Alexander von Humboldt Foundation under the auspices of the Max Planck Research Award which is funded by the Federal Ministry of Education and Research.
Paper cited: Liu, J et al. "Triggerable Tough Hydrogels for Gastric Resident Dosage Forms." Nature Communications DOI: 10.1038/s41467-017-00144-z
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits and nearly 46,000 inpatient stays, is the largest birthing center in Massachusetts and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 3,000 researchers, including physician-investigators and renowned biomedical scientists and faculty supported by nearly $666 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.